|
|
Post by JHam on Jun 8, 2020 13:20:03 GMT
After reviewing this all of yesterday, I just opened a position here pre-market. Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. It is developing a product for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas. o/s - 16.94M Insiders/Institutional ownership - 74% Float - 5.51M Market cap - $185M Key pointsTheir core technology, RAD, for tattoo removal and cellulite has a potential $10B market. ・> $4B for tattoo removal ・$4B for cellulite reduction These are all late stage with tattoo removal awaiting FDA approval and with cellulite data being released this coming Friday, June 12th. For Keloid the market is 10B but it is still in the proof of concept stage. --- Data for both tattoo removal and cellulite is spectacular. For tattoo・Soliton RAP delivered 75% or greater fading in 100% of patients* after 3 office visits ・Outperformed “laser-only” 100%* of the time For celluliteEfficacy ・100% correct selection of the before and 12-week post-treatment photos by all blinded reviewers ・At 26 weeks, average reduction of the Cellulite Severity Scale (CSS) to 2.93 from 4.27 (p<0.001) Participant Perception of Improvement and Satisfaction ・4 of 5 self-reported improvement ・80% indicated “improved” to “very much improved” Pain ・97% of treatments were rated 0 on a 0 to 10-point pain scale (with 0 being no pain) They are low on cash and will likely need to do a raise soon. Although due to COVID19 they think they now have a cash runway until the end of the year. I am not too concerned about a raise because... ...My thesis for investing in this one is not only due to the near term data catalyst this week, but one of the major players in the aesthetics space is Zeltiq. Zeltiq, was acquired by Allergan in 2017 for $2.48B for their "CoolScultping" technology. CoolSculpting is a fat slim-down technology but does not work for tattoo removal or cellulite, as SOLY's RAD does. Most importantly, some of Zeltiq's management and several of the directors are from Zeltiq! SOLY does license RAD from MD Anderson Cancer Center (who the CEO of SOLY has a close relationship with), and will have to pay an upper single digit royalty upon commercialization. Gross margins will need to increase to make it to profitability. However, 1% of current worldwide market for tattoo removal alone would justify the current stock price at 4x revenue. Imo, they have the potential to capture much more than 1%, and that is not even including cellulite. Please do your own DD. This is a good place to start. Corporate presentation: d1io3yog0oux5.cloudfront.net/_60f516d7619cf5e4ff64f6e8dc2c0b89/soliton/db/295/2277/pdf/SOLY+INVESTOR+Deck+5.13.20+%281%29.pdfSummary of technology (look at the before/after photos, watch the video): www.soliton.com/technology/Bullish article: seekingalpha.com/article/4324752-soliton-solid-play-on-tattoo-removal-opportunity-in-2020Bearish article (I'd argue that he doesn't really understand the full depth of the technology, nor recognize Zeltiq management moving to SOLY. He assumes SOLY is market standard and not a game changer): seekingalpha.com/article/4340177-soliton-looks-like-easy-short-one-caveat |
|
|
|
Post by selluwud on Jun 8, 2020 15:10:17 GMT
After reviewing this all of yesterday, I just opened a position here pre-market. Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. It is developing a product for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas. o/s - 16.94M Insiders/Institutional ownership - 74% Float - 5.51M Market cap - $185M Key pointsTheir core technology, RAD, for tattoo removal and cellulite has a potential $10B market. ・> $4B for tattoo removal ・$4B for cellulite reduction These are all late stage with tattoo removal awaiting FDA approval and with cellulite data being released this coming Friday, June 12th. For Keloid the market is 10B but it is still in the proof of concept stage. --- Data for both tattoo removal and cellulite is spectacular. For tattoo・Soliton RAP delivered 75% or greater fading in 100% of patients* after 3 office visits ・Outperformed “laser-only” 100%* of the time For celluliteEfficacy ・100% correct selection of the before and 12-week post-treatment photos by all blinded reviewers ・At 26 weeks, average reduction of the Cellulite Severity Scale (CSS) to 2.93 from 4.27 (p<0.001) Participant Perception of Improvement and Satisfaction ・4 of 5 self-reported improvement ・80% indicated “improved” to “very much improved” Pain ・97% of treatments were rated 0 on a 0 to 10-point pain scale (with 0 being no pain) They are low on cash and will likely need to do a raise soon. Although due to COVID19 they think they now have a cash runway until the end of the year. I am not too concerned about a raise because... ...My thesis for investing in this one is not only due to the near term data catalyst this week, but one of the major players in the aesthetics space is Zeltiq. Zeltiq, was acquired by Allergan in 2017 for $2.48B for their "CoolScultping" technology. CoolSculpting is a fat slim-down technology but does not work for tattoo removal or cellulite, as SOLY's RAD does. Most importantly, some of Zeltiq's management and several of the directors are from Zeltiq! SOLY does license RAD from MD Anderson Cancer Center (who the CEO of SOLY has a close relationship with), and will have to pay an upper single digit royalty upon commercialization. Gross margins will need to increase to make it to profitability. However, 1% of current worldwide market for tattoo removal alone would justify the current stock price at 4x revenue. Imo, they have the potential to capture much more than 1%, and that is not even including cellulite. Please do your own DD. This is a good place to start. Corporate presentation: d1io3yog0oux5.cloudfront.net/_60f516d7619cf5e4ff64f6e8dc2c0b89/soliton/db/295/2277/pdf/SOLY+INVESTOR+Deck+5.13.20+%281%29.pdfSummary of technology (look at the before/after photos, watch the video): www.soliton.com/technology/Bullish article: seekingalpha.com/article/4324752-soliton-solid-play-on-tattoo-removal-opportunity-in-2020Bearish article (I'd argue that he doesn't really understand the full depth of the technology, nor recognize Zeltiq management moving to SOLY. He assumes SOLY is market standard and not a game changer): seekingalpha.com/article/4340177-soliton-looks-like-easy-short-one-caveatLooking like a good pick going into today, up 10%, Good Luck |
|
|
|
Post by JHam on Jun 9, 2020 14:35:24 GMT
Bought some more if this today at $12.01. Data released at the AAD meeting this Friday at 3pm, to those in attendance only. They’ll PR it on the 15th, but I have a feeling the word will get out on Friday.
|
|
|
|
Post by JHam on Jun 10, 2020 18:41:41 GMT
Averaged up again here. Cost basis is $12.30 now with a pretty solid position. I watched this video with the CEO and I could feel him tugging at my heart strings  www.soliton.com |
|
|
|
Post by JHam on Jun 12, 2020 18:14:33 GMT
Data for the cellulite trial out today at 3pm, but they won’t PR it until Monday.
|
|
|
|
Post by selluwud on Jun 12, 2020 18:39:18 GMT
Data for the cellulite trial out today at 3pm, but they won’t PR it until Monday. Don't you think someone in attendance at the announcement will repeat it? Or will they be under some type of silence/NDA agreement. |
|
|
|
Post by selluwud on Jun 12, 2020 19:09:43 GMT
Data for the cellulite trial out today at 3pm, but they won’t PR it until Monday. Don't you think someone in attendance at the announcement will repeat it? Or will they be under some type of silence/NDA agreement. They are going to release the information concurrent with the meeting on their web  site: |
|
|
|
Post by JHam on Jun 12, 2020 19:47:58 GMT
Data for the cellulite trial out today at 3pm, but they won’t PR it until Monday. Don't you think someone in attendance at the announcement will repeat it? Or will they be under some type of silence/NDA agreement. They just put it on their website. The data is spectacular. Have a look at the CEO’s video summary. secure.soliton.com/cellulite/?website-pop-up |
|
|
|
Post by JHam on Jun 12, 2020 19:56:20 GMT
They are going to PR it on Monday, and I feel almost certain that they’ll do a huge raise to coincide with this data. I’m actually not too concerned about that either. They can tackle 2 (potentially 3) conditions with one machine, that is superior and much cheaper than the current standard of care, in waaaaay fewer sessions, and it is noninvasive. They already have FDA 501 approval for the tattoo removal indication, but they decided to hold back on launching during COVID. Now they resubmitted it to include cellulite. Two-fer-one  The two indications represent and $8B+, which if SOLY captures just 1% of would still justify the current pps. |
|
|
|
Post by JHam on Jun 13, 2020 7:24:04 GMT
Allergan paid $2.48B for Zeltiq and their cryotherapy "Coolscultping" technology which has medium side effects and is not effective on cellulite.
Based on this new data (which was only from one treatment), RAD has the best results seen to date on cellulite, no side effects, (just minor discomfort at the spot of treatment from the pulses), noninvasive, it's cheap, and takes less sessions than the standard of care.
AAaand that same Zeltiq team who was there when Allergan acquired them, are now all at Soliton.
Aaaand cellulite isn't even lead candidate. They already have 510K approval from the FDA for tattoo removal using the same device.
So if big pharma paid $2.48B for an inferior product, what would they pay for a better product that also had use for another indication that is already approved on a limited basis with am even larger market?
We haven't even talked about other indications in the pipeline like Keliod, which is a $10B market and in the clinic.
The plan now is to hold this one for the long haul. Even through anticipated dilution in the short term.
|
|
|
|
Post by JHam on Jun 16, 2020 19:39:48 GMT
Allergan paid $2.48B for Zeltiq and their cryotherapy "Coolscultping" technology which has medium side effects and is not effective on cellulite. Based on this new data (which was only from one treatment), RAD has the best results seen to date on cellulite, no side effects, (just minor discomfort at the spot of treatment from the pulses), noninvasive, it's cheap, and takes less sessions than the standard of care. AAaand that same Zeltiq team who was there when Allergan acquired them, are now all at Soliton. Aaaand cellulite isn't even lead candidate. They already have 510K approval from the FDA for tattoo removal using the same device. So if big pharma paid $2.48B for an inferior product, what would they pay for a better product that also had use for another indication that is already approved on a limited basis with am even larger market? We haven't even talked about other indications in the pipeline like Keliod, which is a $10B market and in the clinic. The plan now is to hold this one for the long haul. Even through anticipated dilution in the short term. As usual, changed my mind this morning and dumped this for an 11% profit. Not much, but I saw another opportunity I wanted to try and take advantage of (which I was too late to). Looking to get back in here if it drops under $11. |
|
|
|
Post by selluwud on Jun 25, 2020 20:34:32 GMT
Allergan paid $2.48B for Zeltiq and their cryotherapy "Coolscultping" technology which has medium side effects and is not effective on cellulite. Based on this new data (which was only from one treatment), RAD has the best results seen to date on cellulite, no side effects, (just minor discomfort at the spot of treatment from the pulses), noninvasive, it's cheap, and takes less sessions than the standard of care. AAaand that same Zeltiq team who was there when Allergan acquired them, are now all at Soliton. Aaaand cellulite isn't even lead candidate. They already have 510K approval from the FDA for tattoo removal using the same device. So if big pharma paid $2.48B for an inferior product, what would they pay for a better product that also had use for another indication that is already approved on a limited basis with am even larger market? We haven't even talked about other indications in the pipeline like Keliod, which is a $10B market and in the clinic. The plan now is to hold this one for the long haul. Even through anticipated dilution in the short term. As usual, changed my mind this morning and dumped this for an 11% profit. Not much, but I saw another opportunity I wanted to try and take advantage of (which I was too late to). Looking to get back in here if it drops under $11. You were right about a raise, you may get to get back in at your number, just hit the 9s in post market. eresearch.fidelity.com/eresearch/evaluate/news/basicNewsStory.jhtml?symbols=SOLY&storyid=202006251601PR_NEWS_USPR_____DA47074&provider=PR_NEWS_&product=USPR____&sb=1 |
|
|
|
Post by JHam on Jun 26, 2020 1:42:03 GMT
Yeah you could see this coming from a mile away. Not sure why they didn’t announce the amount they intend to raise. Strange. |
|
|
|
Post by JHam on Jun 26, 2020 14:45:41 GMT
|
|
|
|
Post by JHam on Jun 27, 2020 7:05:22 GMT
$7.56!! Not even a $130M market cap for a potential multi-billion dollar company that is about to file a 510K with the FDA, and hopefully launch next year. The pricing for the raise was $8.30 so we are definitely in the “vulch”-zone here.
With $35M worth of dilution now out of the way (should close on Monday), it will be hard not to buy this again if it stays at this price early next week.
|
|
|
|
Post by JHam on Jun 27, 2020 7:49:18 GMT
The Offering
Common stock offered by us
4,216,868 shares of our common stock.
Underwriters’ option to purchase additional shares of common stock
W
e have granted the underwriters a 30-day option to purchase up to additional shares of common stock from us at the public offering price, less the underwriting discount.
Common stock to be outstanding after this offering
21,189,943 shares (21,822,473 shares if the underwriters exercise their option in full).
Use of Proceeds
We intend to use the net proceeds of this offering for support costs to launch our products including sales and marketing spending; development of our device to be sold commercially including tooling and fixtures for manufacturing and inventory build; regulatory and clinical efforts to expand our pipeline; brand development spending; and for working capital and general corporate purposes. See the caption “Use of Proceeds” on page S-8.
Risk Factors
Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-5 of this prospectus supplement and the risk factors incorporated by reference into this prospectus supplement and the accompanying prospectus.
Nasdaq Capital Market Symbol
“SOLY”
The number of shares of our common stock expected to be outstanding after this offering is based on 16,973,075 shares of common stock outstanding as of June 24, 2020, and excludes, as of that date, the following:
•1,324,608 shares of common stock underlying outstanding warrants having an average exercise price of $11.32 per share;
•3,316,050 shares of common stock underlying outstanding options at an average exercise price of $3.90 per share; and
•848,950 shares of common stock available for future issuance under the Soliton, Inc. 2018 Stock Plan.
Except as otherwise indicated herein, all information in this prospectus supplement assumes no exercise of the outstanding options or the warrants described above and no exercise by the underwriters of their option to purchase additional shares of common stock.
S-4
|
|
|
|
Post by JHam on Jun 27, 2020 7:55:04 GMT
The Offering Common stock offered by us
4,216,868 shares of our common stock. Underwriters’ option to purchase additional shares of common stock W e have granted the underwriters a 30-day option to purchase up to additional shares of common stock from us at the public offering price, less the underwriting discount. Common stock to be outstanding after this offering
21,189,943 shares (21,822,473 shares if the underwriters exercise their option in full).Use of Proceeds We intend to use the net proceeds of this offering for support costs to launch our products including sales and marketing spending; development of our device to be sold commercially including tooling and fixtures for manufacturing and inventory build; regulatory and clinical efforts to expand our pipeline; brand development spending; and for working capital and general corporate purposes. See the caption “Use of Proceeds” on page S-8. Risk Factors Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-5 of this prospectus supplement and the risk factors incorporated by reference into this prospectus supplement and the accompanying prospectus. Nasdaq Capital Market Symbol “SOLY” The number of shares of our common stock expected to be outstanding after this offering is based on 16,973,075 shares of common stock outstanding as of June 24, 2020, and excludes, as of that date, the following: •1,324,608 shares of common stock underlying outstanding warrants having an average exercise price of $11.32 per share; •3,316,050 shares of common stock underlying outstanding options at an average exercise price of $3.90 per share; and •848,950 shares of common stock available for future issuance under the Soliton, Inc. 2018 Stock Plan. Except as otherwise indicated herein, all information in this prospectus supplement assumes no exercise of the outstanding options or the warrants described above and no exercise by the underwriters of their option to purchase additional shares of common stock. S-4 Again, this same group sold Zeltiq (coolsculpting) to Allergan for $2.84B. Coolsculpting has its limitations compared to RAD, and RAD's main indication is for tattoo removal. So being very conservative here, let's say, $1.5B for cellulite (competition for coolsculpting), and $3B for tattoo removal. That's $4.5B for those 2 indications, not even considering keloid, which is a $10B market. With 21.8M shares out, that would be a $206 pps. Who knows if it ever gets there, but at the current $128M market valuation, there is definitely room for this to grow. |
|
|
|
Post by magnus123 on Jun 27, 2020 7:56:39 GMT
I had this on my watchlist, but never bought. This offering is pure barbarism! Sad for all former shareholders, but maybe a nice opportunity for us? I have currently not enough funds to buy here, but its definitely worth a look.
|
|
|
|
Post by selluwud on Jun 27, 2020 10:58:14 GMT
I'm in, picked up some around 8.00 and will wait for recovery.
|
|
|
|
Post by JHam on Jun 27, 2020 11:00:29 GMT
I had this on my watchlist, but never bought. This offering is pure barbarism! Sad for all former shareholders, but maybe a nice opportunity for us? I have currently not enough funds to buy here, but its definitely worth a look. Yeah I'm glad I got when I did. I'd have no problem buying at these levels, but I also need to wait to sell some other stocks before jumping back in here. |
|
The two indications represent and $8B+, which if SOLY captures just 1% of would still justify the current pps. 